Site-Specific and Country-of-Origin Labeling for Pharmaceutical Manufacturing

Abstract

There is increasing concern about the quality of pharmaceuticals, especially generics made in Asia. Popular books and news reports have the public questioning the quality of pharmaceuticals. Recalls and import bans shake confidence in medications, particularly for active pharmaceutical ingredients and finished dosage forms made outside the United States. The Food and Drug Administration uses geography to allocate resources for manufacturing surveillance. Site of manufacturing labeling, including the country, could be linked to the facility’s quality score to assess the risk of poor quality. Clinicians should advocate for legal and regulatory changes to increase the transparency of pharmaceutical manufacturing of products.

Keywords

FDA generic drugs brand drugs biologicals pharmaceutical manufacturing

Get full access to this article

View all access options for this article.

References

Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, US Food & Drug Administration. Report on the state of pharmaceutical quality, 2018: assuring quality medicines are available for the American public. Date unknown. Accessed October 28, 2021. https://www.fda.gov/media/125001/download.

Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, US Food & Drug Administration. Report on the state of pharmaceutical quality: fiscal year 2020: assuring quality medicines are available to the American public. Published August 2021. Accessed October 18, 2021. https://www.fda.gov/media/151561/download.

Eban

Bottle of Lies: The Inside Story of the Generic Drug Boom. New York, NY: HarperCollins Publishers; 2019.

White

CM.

Generic drugs are not as safe as FDA wants you to believe. Ann Pharmacother. 2020;54(3):283-286. doi:10.1177/1060028019881692.

Flavin

Happe

Hatton

. Meeting report: an exploration into the scientific and regulatory aspects of pharmaceutical drug quality in the United States. Expert Opin Drug Saf. Published online December 31, 2021. doi: 10.1080/14740338.2022.2020244.

The White House. Building resilient supply chains, revitalizing American manufacturing, and fostering broad-based growth: 100-day reviews under executive order 14017. Published June 2021. Accessed October 19, 2021. https://www.whitehouse.gov/wp-content/uploads/2021/06/100-day-supply-chain-review-report.pdf.

Country of origin labeling for fish and shellfish. 7 USC 1621 § 60.200. January 1, 2021. Accessed October 28, 2021. https://www.govinfo.gov/content/pkg/CFR-2021-title7-vol3/xml/CFR-2021-title7-vol3-part60.xml.

Chang

Country of origin labeling: history and public choice theory. Food Drug Law J. 2009;64(4):693-715.

21 CFR § 201.1–drugs; name and place of business of manufacturer, packer or distributor. April 1, 2021 Accessed October 28, 2021. https://www.govinfo.gov/content/pkg/CFR-2021-title21-vol7/xml/CFR-2021-title21-vol7-sec701-12.xml.

10.

The Pew Charitable Trusts. FDA globalization act of 2009: drug safety provisions. Published June 10, 2009. Accessed October 27, 2021. https://www.pewtrusts.org/en/research-and-analysis/issue-briefs/2009/06/10/fda-globalization-act-of-2009-drug-safety-provisions.

11.

Brechtelsbauer

Pennell

Durham

Hertig

Weber

RJ.

Review of the 2015 drug supply chain security act. Hosp Pharm. 2016;51(6):493-500. doi:10.1310/hpj5106-493.

12.

Hatton

Leighton

Englander

. Countries manufacturing pharmaceuticals for the US market: a 10-year analysis of public data. Ann Pharmacother. Published online January 18, 2022. doi: 10.1177/10600280211069540.

13.

21 CFR § 314.430 availability for public disclosure of data and information in an application or abbreviated application. n.d. Accessed December 1, 2021. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-314/subpart-G/section-314.430.

14.

Cama

Leszczynski

Tang

, et al To push or pull? In a post-COVID world, supporting and incentivizing antimicrobial drug development must become a governmental priority. ACS Infect Dis. 2021;7:2029-2042. doi:10.2021/acsinfecdis.0c00681.

15.

US Food & Drug Administration. Advanced manufacturing. n.d. Accessed October 27, 2021. https://www.fda.gov/emergency-preparedness-and-response/mcm-issues/advanced-manufacturing.

16.

Phlow Corporation. Phlow corporation awarded $354 million HHS/ASPR/BARDA contract to manufacture essential medicines in shortage: move strengthens America’s supply chain and supports COVID-19 response. Published May 19, 2020. Accessed October 27, 2021. https://www.prnewswire.com/news-releases/phlow-corporation-awarded-354-million-hhsasprbarda-contract-to-manufacture-essential-medicines-in-shortage-301061648.html.

17.

US Food & Drug Administration. Guidance for industry: labeling for human prescription drug and biological products—implementing the PLR content and format requirements. Published February 2013. Accessed October 27, 2021. https://www.fda.gov/media/71836/download.

18.

21 CFR § 206 imprinting of solid oral dosage form drug products for human use. Date unknown. Accessed October 28, 2021. https://www.govinfo.gov/content/pkg/CFR-2021-title21-vol4/xml/CFR-2021-title21-vol4-sec206-10.xml.

19.

Dabestani

Bazil

Costantino

, et al Evidence-based quality scores for rating drug products and their utility in health systems. medRxiv. 2020. doi:10.1101/2020.05.22.20110775.

20.

Eban

Salzman

. In generic drug plants in China and India, data falsification is still a problem. STAT. October 29, 2019. Accessed October 19, 2021. https://www.statnews.com/2019/10/29/data-falsification-still-problematic-china-india-generic-drug-plants/.

21.

US Government Accountability Office. Testimony before the subcommittee on oversight and investigations, committee on energy and commerce, house of representatives. Drug safety. Preliminary findings indicate persistent challenges with FDA foreign inspection: statement of Mary Denigan-Macauley. Published December 10, 2019. Accessed November 24, 2021. https://www.gao.gov/assets/gao-20-262t.pdf.